AlexSecret/iStock via Getty Images
- TRex Bio (TRXB), a clinical-stage biotechnology company focused on developing immunoregulatory medicines, priced its IPO at $14 per share, expecting to raise ~$116.7M in gross proceeds.
- The company is offering 8.33 million shares, with the stock expected to begin trading on the Nasdaq Global
